New hope for Hard-to-Treat colorectal cancer: targeted combo trial launches
NCT ID NCT06838338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called JAB-21822, which targets a specific genetic mutation (KRAS G12C), combined with standard chemotherapy and bevacizumab. The study includes 30 Chinese patients with advanced colorectal cancer that has not responded to first-line treatment. The goal is to see if this combination can shrink tumors and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JAB-21822 (a KRAS G12C inhibitor) combined with standard second-line chemotherapy (FOLFIRI or FOLFOX) and bevacizumab
What this could lead to
If successful, this could offer a new treatment option for Chinese patients with KRAS G12C colorectal cancer who have run out of standard options.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. The combination may cause significant side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
-
Fudan University Shanghai Cancer Center
Shanghai, China
-
Peking University Cancer Hospital (Inner Mongolia Campus)/Afffliated Cancer Hospital of Inner Mongolia Medical University
Hohhot, China
-
Peking University First Hospital
Beijing, China